Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 2
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Abatacept increases T cell exhaustion in early RA individuals who carry HLA risk alleles.
Long SA, Muir VS, Jones BE, Wall VZ, Ylescupidez A, Hocking AM, Pribitzer S, Thorpe J, Fuchs B, Wiedeman AE, Tatum M, Lambert K, Uchtenhagen H, Speake C, Ng B, Heubeck AT, Torgerson TR, Savage AK, Maldonado MA, Ray N, Khaychuk V, Liu J, Linsley PS, Buckner JH. Long SA, et al. Front Immunol. 2024 Apr 8;15:1383110. doi: 10.3389/fimmu.2024.1383110. eCollection 2024. Front Immunol. 2024. PMID: 38650930 Free PMC article.
Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review.
Felton JL, Redondo MJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GSF, Harris-Kawano A, Perez D, Saeed Z, Hoag B, Jain R, Evans-Molina C, DiMeglio LA, Ismail HM, Dabelea D, Johnson RK, Urazbayeva M, Wentworth JM, Griffin KJ, Sims EK; ADA/EASD PMDI. Felton JL, et al. Commun Med (Lond). 2024 Apr 6;4(1):66. doi: 10.1038/s43856-024-00478-y. Commun Med (Lond). 2024. PMID: 38582818 Free PMC article.
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review.
Felton JL, Griffin KJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GSF, Evans-Molina C, DiMeglio LA, Ismail HM, Steck AK, Dabelea D, Johnson RK, Urazbayeva M, Gitelman S, Wentworth JM, Redondo MJ, Sims EK; ADA/EASD PMDI. Felton JL, et al. Commun Med (Lond). 2023 Oct 5;3(1):130. doi: 10.1038/s43856-023-00357-y. Commun Med (Lond). 2023. PMID: 37794169 Free PMC article.
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
Mathieu C, Wiedeman A, Cerosaletti K, Long SA, Serti E, Cooney L, Vermeiren J, Caluwaerts S, Van Huynegem K, Steidler L, Blomme S, Rottiers P, Nepom GT, Herold KC; AG019-T1D-101 Trial Investigators. Mathieu C, et al. Diabetologia. 2024 Jan;67(1):27-41. doi: 10.1007/s00125-023-06014-2. Epub 2023 Oct 2. Diabetologia. 2024. PMID: 37782353 Free PMC article. Clinical Trial.
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.
Yang JHM, Ward-Hartstonge KA, Perry DJ, Blanchfield JL, Posgai AL, Wiedeman AE, Diggins K, Rahman A, Tree TIM, Brusko TM, Levings MK, James EA, Kent SC, Speake C, Homann D, Long SA; Immunology of Diabetes Society T-Cell Cytometry Group. Yang JHM, et al. Eur J Immunol. 2022 Mar;52(3):372-388. doi: 10.1002/eji.202049067. Epub 2022 Jan 28. Eur J Immunol. 2022. PMID: 35025103 Free PMC article.